Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
about
Molecular imaging for cancer diagnosis and surgery.A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner?PET/CT in Oncology: Current Status and Perspectives.A fluoride-derived electrophilic late-stage fluorination reagent for PET imaging.PET/CT and breast cancer.PET-CT guided curative conformal radiation therapy in limited stage small cell lung cancerInitial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancerInitial investigation of ¹⁸F-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgeryImproved Benefit of SPECT/CT Compared to SPECT Alone for the Accurate Localization of Endocrine and Neuroendocrine Tumors.Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review.Advances in diagnostic imaging for peripheral arterial disease.Convergence technology in cancer medicine.Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.Molecular imaging for personalized cancer care.Positron emission tomography of the vulnerable atherosclerotic plaque in man--a contemporary reviewPET/CT in therapy evaluation of patients with lung cancer.Follow-Up Imaging: Molecular Imaging is Likely Best as a Single Modality, but Multimodality Imaging is the FutureImage-guided surgery using multimodality strategy and molecular probes.Followup of a solid solitary pulmonary nodule with low metabolic activityUse of [(18)F]Fluoro-2-deoxy-d-glucose Positron Emission Tomographic Imaging in the National Lung Screening Trial.Fever of unknown origin: a retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT.The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.Report on the development and application of PET/CT in mainland ChinaWhen and how often should PET scans be performed in the management of cervical cancer?Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.A catalytic fluoride-rebound mechanism for C(sp3)-CF3 bond formation.Prognostic value of pre-treatment 18F-FDG PET uptake for nasopharyngeal carcinoma.Prognostic value of pre-treatment 18F-FDG-PET uptake in small-cell lung cancer.Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma.Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.Imaging in oncology--over a century of advances.Demonstrating the benefits of clinical nuclear imaging: is it time to add economic analysis?[Importance of PET/CT in lymphoma diagnostics].Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial.
P2860
Q27687291-E5BA8609-1A79-4F38-80E1-79F0DCD82F9AQ30497087-8498C3EF-7576-4070-B28A-C6ACD0EED24CQ33665109-3AB51C3F-CE62-4A46-949C-01BD7973CBF1Q34230071-4D329A94-AA98-4221-AD43-51621F130BECQ34256370-73433A16-3BB5-4C7B-9982-0D3AD29DC3A1Q35290430-90339B49-683D-4DF7-9986-2EA5693759B9Q35584948-003233AC-8379-4E23-A250-121FE37DC714Q36297818-295BE5D7-C150-4BCE-BF51-D6DCE3CC82EBQ36664675-94C98F64-B1A7-4CC3-A700-D4C1BA2A2C07Q37702368-4525BBD2-EB90-4CFF-B40E-EC1D33E0F644Q37799364-2C065023-C1A9-4F19-88B2-D326C95BC1F6Q37850452-CE9666CE-2356-472E-B5CE-EC29F2973D59Q37968594-08F77786-A8B5-47F8-B795-10EC4CA6B292Q37999206-EB9254A8-10AF-4F64-A884-2F28FF171063Q38167348-9B32F477-DD22-4B09-9820-4CEF0AD6007AQ38202189-146B16D9-EFAC-42BA-9CE9-B0F241A80379Q38474606-BAA25CB8-20BC-4BB6-964E-D5B0F1676369Q38520183-57C8ABEE-4D6C-4362-8377-4C7EB36F8271Q39664938-E4D85B49-31DB-4ACB-846D-E4528E160BC5Q39765716-C82719F0-B4EC-4133-9845-8CCD0C14A33FQ40313277-15624F8F-75EF-4E6A-974A-4CE60B54900AQ41053000-14B1919F-E1F4-4DA7-AEFB-3D7F8273DEF8Q42362793-6EDB0178-4657-4AC2-82E5-A48ED6E16005Q42964660-646E07C8-EB12-492F-B550-31A39E9FBA0FQ45394964-1FDBB993-A25E-4654-B42D-9DD9FD0D8B8AQ46626309-606B65F5-550F-41B8-B73F-5FA940107C36Q49607757-5402B87B-F02D-43C4-92AB-AB7E518E9B1BQ50639405-61E4B9B5-CA44-4A41-9D93-47EB5D3E123BQ51032948-517C10DC-08FE-499E-ACCF-6F0AC247B5B2Q51408712-7D5DA3EC-7063-48C0-B5F3-93F16933BDCBQ51539924-97B6DEBF-F7E6-45A7-A3B3-679595D014F9Q53061052-DBB852D0-A5CC-4DB7-96CA-5D75949D0B67Q53165027-698DD8DF-689A-4D82-9369-18151EDDA55BQ53251677-99384D33-5C57-4CD6-B18F-AE6C58F45983
P2860
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
@en
type
label
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
@en
prefLabel
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
@en
P2093
P1476
Economic evaluation of PET and PET/CT in oncology: evidence and methodologic approaches.
@en
P2093
Andreas K Buck
Bernd Joachim Krause
Jonas Schreyögg
Ken Herrmann
Tobias Dechow
Tom Stargardt
P304
P356
10.2967/JNUMED.108.059584
P407
P577
2010-02-11T00:00:00Z